Abbott Labs might be an M&A target; Pharma overruled as U.S. trade rep nixes 'worst offender' status for India;

@FiercePharma: Takeda wins $70M from Japan to bump up H5N1 vaccine production. More | Follow @FiercePharma

@TracyStaton: ICYMI: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Story | Follow @TracyStaton

@EricPFierce: Reckitt Benckiser abandons talks with Merck. Sounds like Bayer is left standing in battle for OTC unit. | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FiercePharmaMarketing with stories from @TracyStaton, @CarlyHFierce and @EmilyWFierce. Report | Follow @CarlyHFierce

> Could Abbott Laboratories ($ABT) become the next merger target in the pharma industry's M&A wave? If the company doesn't boost returns, then maybe so. Report

> India dodged a bullet--and pharma lobbyists suffered a defeat--when the U.S. Trade Rep decided not to slap a "worst offender" tag on the country in its latest scorecard on intellectual property protections. Report

> Consolidation in the U.S. pharma business is hurting medium-size Indian drugmakers as newly dominant players force generic drug prices down. Report

> U.S.-based Alexza Pharmaceuticals ($ALXA) said its partner Medivir Ferrer rolled out its new inhaled antipsychotic drug, Adasuve, in four Nordic countries. Report (sub. req.)

> The onset of Obamacare has boosted consumer spending on health services, with purchases soaring by 9.9% at an annualized rate. Report

Medical Device News

@FierceMedDev: Boston Scientific rolls out next-gen stent system in Japan. Article | Follow @FierceMedDev

@VarunSaxena2: Parkinson's is a hot area for drug delivery; many companies are trying to deliver established drugs in new ways to treat "off" episodes. | Follow @VarunSaxena2

@EmilyWFierce: Endo will pay $830M to resolve a majority of its vaginal mesh cases. Story | Follow @EmilyWFierce

@MichaelGFierce: Imaging technique maps transdermal drug migration. Story from FierceDrugDelivery | Follow @MichaelGFierce

> HeartWare warns about battery safety in its ventricular assist device. Story

> Hologic narrows its losses on the crawl toward growth. News

Biotech News

@FierceBiotech: Can anything prevent $PFE's megamerger with $AZN? More | Follow @FierceBiotech

@JohnCFierce: Merrimack heads to the FDA after scoring positive PhIII for pancreatic cancer. Article | Follow @JohnCFierce

@DamianFierce: AstraZeneca's "mild-mannered Swede" stands up to Pfizer and dismisses Big Pharma's sudden embrace of big deals. More | Follow @DamianFierce

@EmilyMFierce: Looking to sales growth, Merck rolls out vaccine adherence plan. Story | Follow @EmilyMFierce

> Amid Zohydro controversy, Teva, Purdue and Pfizer race ahead with new pain drugs. Article

> VC Lightstone lands $172M with an eye on biotech startups. More

> Shire bags an early-stage fibrosis drug in $75M Fibrotech buyout. News

Pharma Manufacturing News

> New York men indicted for selling counterfeit and unapproved drugs in U.S. More

> Hospira makes progress on plant problems, reports improved financials. Report

> Taro expands Canada plant with help from Ontario. More

> Boehringer Ingelheim works a deal with Saudi firms to package its products. Story

> WuXi PharmaTech expands cell therapy manufacturing in U.S. Article

Vaccines News

> Looking to sales growth, Merck rolls out vaccine adherence plan. Report

> Experts: MERS vaccine is possible--but is it worth it? Story

> Need for malaria vaccine grows as climate change threatens disease spread. More

> Sanofi turns out positive PhIII data in quest for dengue blockbuster. Article

> Pentaxim supply delay weighs down Sanofi earnings. News

And Finally... Another reason to drink coffee: It may cut your risk of Type 2 diabetes. Report (sub. req.)

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.